Esperion Therapeutics (ESPR) PT Lowered to $114 at Needham & Company
Tweet Send to a Friend
Needham & Company analyst Chad Messer lowered the price target on Esperion Therapeutics (NASDAQ: ESPR) to $114.00 (from $134.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
